Michael Newnham

Michael Newnham is an Associate Clinical Professor in Respiratory Medicine within the Applied Health Sciences faculty at University of Birmingham. His academic career spans clinical medicine and research with a focus on respiratory diseases and data-driven approaches to healthcare.

His educational background includes:

• Bachelor of Medicine and Bachelor of Surgery from University of Birmingham (awarded July 3, 2006)
• Master of Science from University of Birmingham (awarded July 4, 2005)

Dr. Newnham's research interests center on bioinformatics and health data research, genomics, clinical risk prediction, and respiratory disease. His work particularly focuses on alpha-1 antitrypsin deficiency, chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy, and pulmonary embolism. He employs both clinical and computational approaches to develop risk assessment tools and improve patient outcomes in respiratory medicine.

His recent publications (2024-2025) demonstrate a strong focus on pulmonary diseases, particularly alpha-1 antitrypsin deficiency and pulmonary hypertension. His work spans systematic reviews, clinical trials, and development of computational tools, indicating a multidisciplinary approach that bridges clinical medicine with data science. The research shows consistent collaboration with major UK institutions and industry partners.

Dr. Newnham is actively involved in multiple research projects, including both government-funded (NIHR) and industry-sponsored studies. His current projects focus on AATD (Alpha-1 Antitrypsin Deficiency), venous thromboembolism prevention in lung cancer patients, and pulmonary embolism management. These projects reflect his commitment to translating research findings into clinical practice.

He has held external positions at Heartlands Hospital from August 2018 to January 2020, demonstrating his clinical engagement alongside academic work. His research network shows extensive collaboration with UK institutions and international partners, particularly in the field of respiratory medicine and pulmonary vascular diseases.